Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Up 161.6% in January

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 29,166,975 shares, an increase of 161.6% from the December 31st total of 11,149,487 shares. Based on an average daily trading volume, of 84,020,039 shares, the short-interest ratio is presently 0.3 days. Approximately 1,462.7% of the shares of the company are short sold. Approximately 1,462.7% of the shares of the company are short sold. Based on an average daily trading volume, of 84,020,039 shares, the short-interest ratio is presently 0.3 days.

Aspire Biopharma Stock Performance

Shares of ASBP opened at $1.59 on Thursday. The firm has a market capitalization of $4.28 million, a price-to-earnings ratio of -0.08 and a beta of 0.81. The stock’s fifty day moving average is $3.65 and its 200-day moving average is $11.15. Aspire Biopharma has a one year low of $1.42 and a one year high of $632.00.

Aspire Biopharma (NASDAQ:ASBP) last released its earnings results on Friday, November 14th. The company reported ($1.60) EPS for the quarter. The business had revenue of $0.00 million for the quarter.

Wall Street Analyst Weigh In

ASBP has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Wednesday, January 21st. Wall Street Zen upgraded Aspire Biopharma to a “sell” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On Aspire Biopharma

A number of institutional investors have recently added to or reduced their stakes in the company. Crewe Advisors LLC boosted its stake in Aspire Biopharma by 100.0% during the 2nd quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock valued at $169,000 after purchasing an additional 313,427 shares in the last quarter. Optivise Advisory Services LLC lifted its holdings in shares of Aspire Biopharma by 120.9% in the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock valued at $63,000 after buying an additional 128,660 shares during the period. Jane Street Group LLC boosted its stake in Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after buying an additional 131,533 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Aspire Biopharma during the third quarter worth about $28,000. 19.17% of the stock is currently owned by institutional investors and hedge funds.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.